Sagimet Biosciences Inc. (SGMT) SEC Filings & Earnings Calls
EquiReason read 23 Sagimet Biosciences Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Sagimet Biosciences updated investor presentation highlighting denifanstat Phase 3 acne trial success (met endpoints), NDA accepted in China, AURORA trial initiated in US, TVB-3567.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 595.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
22 Oct 20268-K · 7.01Sagimet Biosciences updated investor presentation highlighting denifanstat Phase 3 acne trial success (met endpoints), NDA accepted in China, AURORA trial initiated in US, TVB-3567 Phase 1 completed, and MASH development paused pending non-open
Risks flagged
MASH development paused pending non-dilutive funding
“Further MASH development to be undertaken only upon securing non-dilutive funding” · word for word
Reliance on license partner Ascletis for China development
“Denifanstat Phase 3 trial conducted by Ascletis; NDA accepted by China NMPA”
1 Oct 20268-K · 1.01Underwriting agreement for a public offering of common stock and pre-funded warrants, indicating equity financing.open
Risks flagged
Dilution from equity offering may pressure stock price.
“Underwriting agreement for common stock and pre-funded warrants.”
30 Sep 20268-K · 7.01, 8.01Positive 52-week results from Phase 3 open-label extension trial of denifanstat in acne vulgaris; all primary and secondary endpoints met; NDA accepted by China NMPA.open
Risks flagged
Reliance on license partner Ascletis for China development; regulatory and commercial risks in China.
“conducted by license partner Ascletis BioScience Co. Ltd. in China” · word for word
13 Aug 20268-K · 8.01FDA cleared IND and issued 'Study May Proceed' letter for Phase 3 trial of denifanstat in moderate to severe acne.open
Risks flagged
Clinical trial risk for Phase 3 denifanstat.
“Phase 3 trial initiation; no data yet.”
11 Aug 20268-K · 2.02, 7.01Cash, cash equivalents and marketable securities $258M; Research and development expense $12M; General and administrative expense $4Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q2-2026 | $258M | |
| Research and development expense · Q2-2026 | $12M | |
| General and administrative expense · Q2-2026 | $4M | |
| Net loss · Q2-2026 | $-14M | |
| Gross proceeds from equity financing · Q2-2026 | $175M |
Risks flagged
Clinical trial risk: denifanstat Phase 3 may fail; no approved products.
“Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026.” · word for word
Cash burn: net loss $14M/quarter; runway depends on trial success.
“Net loss for the three months ended June 30, 2026, was $14.0 million.”
11 Aug 202610-QSGMT reported Q2 2026 net loss of $13.95M (worsened 34% YoY) with R&D expenses up 59%, but highlighted positive Phase 3 acne data and strong cash position of $257.6M after April 2026 equity offering.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · Q2-2026 | $-14M | +34% y/y |
| Research and Development Expenses · Q2-2026 | $12M | +59% y/y |
| Cash, Cash Equivalents and Marketable Securities · 2026-06-30 | $258M |
Risks flagged
MASH program halted due to lack of funding
“We will undertake no further clinical development in MASH until non-dilutive financing is obtained.” · word for word
Dependence on single drug candidate denifanstat
“Our lead drug candidate, denifanstat, is an oral once-daily pill and selective FASN inhibitor in development for the treatment of acne, metabolic dysfunction-associated steatohepatitis (MASH) and select forms of cancer.” · word for word
No approved products or revenue
“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word
12 Jun 20268-K · 5.02, 5.07Outstanding shares of Series A common stock 32,017,613open
Figures in the filing · each found in the filing text
| Outstanding shares of Series A common stock · 2026-04-17 | 32,017,613 |
Risks flagged
Board member resignation, though stated as not due to disagreement, could signal governance instability.
“Tim Walbert resigned from the Board effective June 12, 2026, due to other commitments.”
12 May 202610-QSagimet reported Q1 2026 net loss of $10.65M, improved from $18.18M a year ago, with positive Phase 3 acne data and strong cash position.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $11M | -41% y/y |
| Operating cash flow · Q1-2026 | $9M | -41% y/y |
Risks flagged
No approved products; reliance on unproven pipeline
“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word
MASH program paused; dependency on non-dilutive financing
“We will undertake no further clinical development in MASH until non-dilutive financing is obtained.” · word for word
12 May 20268-K · 2.02Cash, cash equivalents and marketable securities $104M; Net loss $-11M (-41% y/y); Research and development expense $7M (-54% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $105M | |
| Net loss · Q1-2026 | $-11M | -41% y/y |
| Research and development expense · Q1-2026 | $7M | -54% y/y |
| General and administrative expense · Q1-2026 | $5M | +4% y/y |
Risks flagged
Clinical-stage biotech with no approved products; reliance on denifanstat and TVB-3567 pipeline.
“Clinical-stage biopharmaceutical company; net loss of $10.7M in Q1 2026; no revenue mentioned.”
28 Apr 20268-K · 1.01Sagimet Biosciences priced a 29.17M share offering at $6.00/share, raising ~$164.5M net to fund Phase 3 acne trial for denifanstat, TVB-3567 through Phase 2, and topical FASN inhibitor IND.open
Figures in the filing · each found in the filing text
| Shares offered · point_in_time | 29,166,700 | |
| Offering price per share · point_in_time | $6.00 | |
| Net proceeds · point_in_time | $165M |
Risks flagged
Dilution risk from large equity offering.
“29,166,700 new shares issued.”
Execution risk for clinical trials funded by proceeds.
“Proceeds used for Phase 3 acne trial and TVB-3567 Phase 2.”
27 Apr 20268-K · 2.02, 7.01, 8.01Sagimet Biosciences provided preliminary unaudited cash position of ~$104.5M as of March 31, 2026, along with strategic and corporate updates. No revenue or earnings metrics disclosed.earningsopen
Figures in the filing · each found in the filing text
| cash, cash equivalents and marketable securities · Q1-2026 | $105M |
21 Apr 20268-K · 5.02, 8.01Sagimet Biosciences announced retirement of CMO Eduardo Martins and appointment of Andreas Grauer as new CMO.open
Risks flagged
Leadership transition in key clinical role may cause temporary uncertainty in pipeline execution.
“CMO change at a clinical-stage biotech; new CMO has relevant experience but transition risk exists.”
21 Apr 2026DEF 14AProxy statement for 2026 annual meeting; no material event beyond routine governance proposals.open
Figures in the filing · each found in the filing text
| Shares Outstanding · 2026-04-17 | 32,017,613 | |
| CEO Base Salary · 2026 | $654000.00 | |
| CEO Target Bonus Percentage · 2025 | 55.0% | |
| Corporate Goal Achievement · 2025 | 85.0% | |
| At-the-Market Offering Capacity · 2025-08 | $75M |
Risks flagged
Early-stage biotechnology company with no approved products; reliance on clinical trial success and regulatory approvals.
“The company is a clinical-stage biotechnology company; its primary asset denifanstat is in Phase 3 for acne in China and Phase 2b for NASH; no approved products.”
Dependence on partner Ascletis for China development and commercialization of denifanstat.
“In January 2026, positive topline results were reported by our license partner for China, Ascletis BioScience Co. Ltd. (Ascletis) in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne in China.” · word for word
Potential dilution from at-the-market offering of up to $75 million.
“In August 2025, we entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market offering, through which we may sell, from time to time at our sole discretion, up to $75.0 million shares of our Series A common stock.” · word for word
11 Mar 20268-K · 2.02, 7.01Released earnings results and quarterly financials; issued a Regulation FD disclosure (forward guidance or material update)earningsopen
Risks flagged
Clinical-stage biotech with no approved products; reliance on denifanstat and TVB-3567; regulatory and clinical trial risks; partnership with Ascletis for China.
“Denifanstat NDA accepted in China but not yet approved; Phase 2 combo trial with resmetirom not yet initiated; forward-looking statements highlight risks.”
11 Mar 202610-KAnnual report (10-K) for fiscal year 2025, detailing clinical trial results and pipeline progress.earningsopen
Figures in the filing · each found in the filing text
| Denifanstat Phase 2b FASCINATE-2: ≥2-point NAS reduction without worsening fibrosis (mITT) · MASH · FY2025 | 52.0% | |
| Denifanstat Phase 2b FASCINATE-2: MASH resolution without worsening fibrosis (mITT) · MASH · FY2025 | 36.0% | |
| Denifanstat Phase 2b FASCINATE-2: Fibrosis improvement ≥1 stage without MASH worsening (mITT) · MASH · FY2025 | 41.0% | |
| Denifanstat Phase 3 acne: Treatment success (IGA 0/1 with ≥2-point decrease) · Acne · FY2025 | 33.2% | |
| Denifanstat Phase 3 acne: Total lesion count change · Acne · FY2025 | -57.4% | |
| Denifanstat Phase 3 acne: Inflammatory lesion count change · Acne · FY2025 | -63.5% | |
| Denifanstat Phase 3 acne: Non-inflammatory lesion count change · Acne · FY2025 | -51.9% | |
| Combination therapy: Histological improvement (NAS ≥2 points) · MASH Combination · FY2025 | 80.0% |
Risks flagged
Clinical trial discontinuation rate
“The incidence of TEAEs leading to treatment discontinuation was 19.6% in the denifanstat group compared to 5.4% in placebo.” · word for word
Regulatory approval uncertainty
“Denifanstat is not yet approved for any indication; further clinical trials and regulatory approvals are required.”
Competition from existing and emerging MASH therapies
“There are few approved treatments for non-cirrhotic MASH and no approved treatments for cirrhotic MASH (F4).” · word for word
2 Feb 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Dependence on partner Ascletis for China development; regulatory approval not guaranteed.
“Ascletis Pharma Inc. announced... positive topline results”
Clinical trial results may not be predictive of final data or regulatory outcomes.
“the risk the topline clinical trials may not be predictive of, and may differ from final clinical data and later-stage clinical trials” · word for word
18 Dec 20258-K · 7.01, 8.01Issued a Regulation FD disclosure (forward guidance or material update); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Clinical trial risks and regulatory uncertainties remain
“Forward-looking statements caution about clinical development risks, regulatory approvals, and competition”
17 Dec 20258-K · 8.01Upfront payment $2M; milestone payments $6Mopen
Figures in the filing · each found in the filing text
| upfront payment · Q4-2025 | $3M | |
| milestone payments · unknown | $6M |
Risks flagged
Dependence on successful evaluation and development of combination product; milestone payments contingent on future events.
“License Agreement includes evaluation period and election by Company; milestones are potential.”
13 Nov 202510-QSagimet Biosciences reported Q3 2025 results with net loss of $12.9M, narrower than prior year, and cash of $125.5M.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-13M | -12% y/y |
| Research and development expenses · Q3-2025 | $10M | -23% y/y |
| General and administrative expenses · Q3-2025 | $5M | +8% y/y |
| Cash, cash equivalents and marketable securities · 2025-09-30 | $126M | |
| Net cash used in operating activities · 9M-2025 | $-34M | +8% y/y |
Risks flagged
No approved products or revenue
“We do not have any products approved for sale and have not generated any revenue from product sales.” · word for word
Reliance on third-party manufacturers and CROs
“We rely and will continue to rely on third parties in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our drug candidates.” · word for word
Need for additional funding
“If we are unable to obtain adequate financing when needed or on terms favorable or acceptable to us, we may be forced to delay, reduce the scope of or eliminate one or more of our research and development programs.” · word for word
Clinical trial risks
“A change in the outcome of any of these or other variables could significantly change our costs and timing associated with the development of our drug candidates.” · word for word
13 Nov 20258-K · 2.02, 7.01Cash, cash equivalents and marketable securities $126M; R&D Expense $10M (-24% y/y); G&A Expense $5M (+10% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q3-2025 | $126M | |
| R&D Expense · Q3-2025 | $10M | -24% y/y |
| G&A Expense · Q3-2025 | $5M | +10% y/y |
| Net Loss · Q3-2025 | $-13M | +12% y/y |
Risks flagged
Clinical development risk: Phase 1 trials may fail; no approved products yet.
“All programs are in early clinical stages; no revenue from product sales.”
Financing risk: Company has no revenue and relies on capital markets for funding.
“Net loss of $12.9M in Q3 2025; cash burn continues.”
Sagimet Biosciences Inc. — questions
- What did Sagimet Biosciences Inc. file recently?
- 23 SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Sagimet Biosciences updated investor presentation highlighting denifanstat Phase 3 acne trial success (met endpoints), NDA accepted in China, AURORA trial initiated in US, TVB-3567 Phase 1 completed, and MASH development paused pending non-
Every figure on this page comes from Sagimet Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.